Feier Liu, DO | |
263 Farmington Ave, Farmington, CT 06030-0001 | |
(860) 679-6700 | |
(860) 679-6736 |
Full Name | Feier Liu |
---|---|
Gender | Female |
Speciality | Psychiatry |
Experience | 7 Years |
Location | 263 Farmington Ave, Farmington, Connecticut |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1104358977 | NPI | - | NPPES |
Facility Name | Location | Facility Type |
---|---|---|
John Dempsey Hospital | Farmington, CT | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
State Of Connecticut | 8022915677 | 194 |
University Of Connecticut Health Center | 3678472016 | 523 |
News Archive
Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced it has achieved its patient enrollment target in its two pivotal phase 3 clinical studies of bremelanotide for the treatment of female sexual dysfunction (FSD).
African-Americans in major U.S. cities are significantly more likely to live in "trauma deserts" with limited access to advanced emergency medical care, according to new research from the University of Chicago Medicine.
As the COVID-19 pandemic progresses with little prospect of immediate relief, a recent study by Johns Hopkins University researchers published on the preprint server medRxiv* in October 2020 discusses the association of Immunoglobulin M (IgM) autoantibodies against the host receptor that binds severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with severe disease via vascular endothelial damage. This could help develop better therapies and prognostic criteria.
A new study by UCSF researchers concludes that media campaigns that portray the tobacco industry in a negative light and that appeal to young adults may be a powerful intervention to decrease young adult smoking.
› Verified 9 days ago
Entity Name | University Of Connecticut Health Center |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1720083769 PECOS PAC ID: 3678472016 Enrollment ID: O20040106000105 |
News Archive
Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced it has achieved its patient enrollment target in its two pivotal phase 3 clinical studies of bremelanotide for the treatment of female sexual dysfunction (FSD).
African-Americans in major U.S. cities are significantly more likely to live in "trauma deserts" with limited access to advanced emergency medical care, according to new research from the University of Chicago Medicine.
As the COVID-19 pandemic progresses with little prospect of immediate relief, a recent study by Johns Hopkins University researchers published on the preprint server medRxiv* in October 2020 discusses the association of Immunoglobulin M (IgM) autoantibodies against the host receptor that binds severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with severe disease via vascular endothelial damage. This could help develop better therapies and prognostic criteria.
A new study by UCSF researchers concludes that media campaigns that portray the tobacco industry in a negative light and that appeal to young adults may be a powerful intervention to decrease young adult smoking.
› Verified 9 days ago
Entity Name | State Of Connecticut |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1669466561 PECOS PAC ID: 8022915677 Enrollment ID: O20041122000596 |
News Archive
Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced it has achieved its patient enrollment target in its two pivotal phase 3 clinical studies of bremelanotide for the treatment of female sexual dysfunction (FSD).
African-Americans in major U.S. cities are significantly more likely to live in "trauma deserts" with limited access to advanced emergency medical care, according to new research from the University of Chicago Medicine.
As the COVID-19 pandemic progresses with little prospect of immediate relief, a recent study by Johns Hopkins University researchers published on the preprint server medRxiv* in October 2020 discusses the association of Immunoglobulin M (IgM) autoantibodies against the host receptor that binds severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with severe disease via vascular endothelial damage. This could help develop better therapies and prognostic criteria.
A new study by UCSF researchers concludes that media campaigns that portray the tobacco industry in a negative light and that appeal to young adults may be a powerful intervention to decrease young adult smoking.
› Verified 9 days ago
Mailing Address | Practice Location Address |
---|---|
Feier Liu, DO 263 Farmington Ave, Farmington, CT 06030-8082 Ph: (860) 679-6700 | Feier Liu, DO 263 Farmington Ave, Farmington, CT 06030-0001 Ph: (860) 679-6700 |
News Archive
Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced it has achieved its patient enrollment target in its two pivotal phase 3 clinical studies of bremelanotide for the treatment of female sexual dysfunction (FSD).
African-Americans in major U.S. cities are significantly more likely to live in "trauma deserts" with limited access to advanced emergency medical care, according to new research from the University of Chicago Medicine.
As the COVID-19 pandemic progresses with little prospect of immediate relief, a recent study by Johns Hopkins University researchers published on the preprint server medRxiv* in October 2020 discusses the association of Immunoglobulin M (IgM) autoantibodies against the host receptor that binds severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with severe disease via vascular endothelial damage. This could help develop better therapies and prognostic criteria.
A new study by UCSF researchers concludes that media campaigns that portray the tobacco industry in a negative light and that appeal to young adults may be a powerful intervention to decrease young adult smoking.
› Verified 9 days ago
William P Shea Iii, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 263 Farmington Ave, Farmington, CT 06030 Phone: 860-679-6700 Fax: 860-679-6736 | |
Kristina Frances Victoria Zdanys, Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 263 Farmington Ave, Psychiatry, Farmington, CT 06030 Phone: 860-679-6700 Fax: 860-679-6736 | |
Marie Carl Eugene, D.O. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 263 Farmington Ave, Neurology Mc-3835, Farmington, CT 06030 Phone: 860-679-4888 Fax: 860-679-1042 | |
Kelly Nicole Stinson, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 10 Talcott Notch Rd, Farmington, CT 06032 Phone: 860-679-6700 Fax: 860-679-6736 | |
Gema Guanco, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 270 Farmington Ave, Suite 309, Farmington, CT 06032 Phone: 860-677-5570 Fax: 860-677-9570 | |
Dr. Asante Kofi Mendes, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 263 Farmington Ave, Farmington, CT 06030 Phone: 860-679-2000 |